Benitec Biopharma (NASDAQ:BNTC) Given New $18.00 Price Target at JMP Securities

Benitec Biopharma (NASDAQ:BNTC) had its price objective hoisted by JMP Securities from $16.00 to $18.00 in a research report sent to investors on Monday, Benzinga reports. The firm currently has a market outperform rating on the biotechnology company’s stock.

A number of other equities research analysts have also recently issued reports on the stock. Guggenheim began coverage on shares of Benitec Biopharma in a report on Thursday, September 12th. They issued a “buy” rating and a $17.00 target price on the stock. Leerink Partners assumed coverage on shares of Benitec Biopharma in a report on Monday, July 22nd. They issued an “outperform” rating and a $13.00 price objective on the stock. Finally, Leerink Partnrs upgraded shares of Benitec Biopharma to a “strong-buy” rating in a research note on Monday, July 22nd. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $22.60.

Benitec Biopharma Price Performance

BNTC stock opened at $9.81 on Monday. Benitec Biopharma has a twelve month low of $2.69 and a twelve month high of $12.89. The business has a 50 day moving average price of $9.13 and a two-hundred day moving average price of $8.33. The company has a market cap of $91.90 million, a price-to-earnings ratio of -5.14 and a beta of 0.90.

Institutional Investors Weigh In On Benitec Biopharma

Several institutional investors and hedge funds have recently bought and sold shares of BNTC. GAMMA Investing LLC raised its position in shares of Benitec Biopharma by 53.0% in the 2nd quarter. GAMMA Investing LLC now owns 5,438 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 1,884 shares in the last quarter. Simplify Asset Management Inc. acquired a new position in Benitec Biopharma during the second quarter valued at approximately $358,000. Janus Henderson Group PLC lifted its stake in Benitec Biopharma by 35.5% during the first quarter. Janus Henderson Group PLC now owns 244,491 shares of the biotechnology company’s stock worth $1,266,000 after purchasing an additional 64,092 shares during the last quarter. Finally, Nantahala Capital Management LLC acquired a new stake in shares of Benitec Biopharma in the 2nd quarter valued at $5,881,000. Institutional investors own 52.19% of the company’s stock.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.